From the laboratory to clinical trials and back again: lessons learned from HIV prevention trials (Q38067443)

28 August 2017

1 reference

title

From the laboratory to clinical trials and back again: lessons learned from HIV prevention trials (English)

1 reference

28 August 2017

prevention of HIV/AIDS

0 references

1 reference

1

Sengeziwe Sibeko

1 reference

28 August 2017

Shokouh Makvandi-Nejad

series ordinal

2

1 reference

28 August 2017

13 December 2012

1 reference

American Journal of Reproductive Immunology

28 August 2017

1 reference

28 August 2017

69 Suppl 1

1 reference

28 August 2017

106-115

1 reference

Setting the stage: host invasion by HIV.

28 August 2017

1 reference

HIV prevention transformed: the new prevention research agenda

21 January 2018

1 reference

Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention

21 January 2018

1 reference

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

21 January 2018

1 reference

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

21 January 2018

1 reference

Preexposure prophylaxis for HIV infection among African women

21 January 2018

1 reference

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

21 January 2018

1 reference

Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

21 January 2018

1 reference

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

21 January 2018

1 reference

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

21 January 2018

1 reference

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

21 January 2018

1 reference

CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck

21 January 2018

1 reference

Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.

21 January 2018

1 reference

Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial

21 January 2018

1 reference

Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women

21 January 2018

1 reference

Critical issues in mucosal immunity for HIV-1 vaccine development

21 January 2018

1 reference

HIV vaccines: lessons learned and the way forward

21 January 2018

1 reference

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.

21 January 2018

1 reference

The immune response during acute HIV-1 infection: clues for vaccine development

21 January 2018

1 reference

Targeting early infection to prevent HIV-1 mucosal transmission.

21 January 2018

1 reference

Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial

21 January 2018

1 reference

Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition

21 January 2018

1 reference

Glycerol monolaurate prevents mucosal SIV transmission

21 January 2018

1 reference

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

21 January 2018

1 reference

Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission

21 January 2018

1 reference

Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections

21 January 2018

1 reference

Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials

21 January 2018

1 reference

Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling

21 January 2018

1 reference

Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study

21 January 2018

1 reference

Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators

21 January 2018

1 reference

Recent observations on HIV type-1 infection in the genital tract of men and women

21 January 2018

1 reference

Assessment of mucosal immunity to HIV-1.

21 January 2018

1 reference

Methodological issues in sampling the local immune system of the female genital tract in the context of HIV prevention trials

21 January 2018

1 reference

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/AJI.12045

1 reference

28 August 2017

1 reference

PubMed ID

23240676